Literature DB >> 12920018

Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity.

Yangbing Zhao1, David Boczkowski, Smita K Nair, Eli Gilboa.   

Abstract

Induction of potent and sustained antiviral or antitumor immunity is dependent on the efficient activation of CD8+ and CD4+ T cells. While dendritic cells constitute a powerful platform for stimulating cellular immunity, presentation of endogenous antigens by dendritic cells transfected with nucleic acid-encoded antigens favors the stimulation of CD8+ T cells over that of CD4+ T cells. A short incubation of mRNA-transfected dendritic cells with antisense oligonucleotides directed against the invariant chain enhances the presentation of mRNA-encoded class II epitopes and activation of CD4+ T-cell responses in vitro and in vivo. Immunization of mice with the antisense oligonucleotide-treated dendritic cells stimulates a more potent and longer lasting CD8+ cytotoxic T-cell (CTL) response and enhances the antitumor efficacy of dendritic cell-based tumor vaccination protocols. Transient inhibition of invariant chain expression represents a simple and general method to enhance the stimulation of CD4+ T-cell responses from endogenous antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12920018     DOI: 10.1182/blood-2003-06-1867

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  10 in total

1.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

2.  Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions.

Authors:  Lisa M Rimsza; Robin A Roberts; Elias Campo; Thomas M Grogan; Silvia Bea; Itziar Salaverria; Andreas Zettl; Andreas Rosenwald; German Ott; H Konrad Muller-Hermelink; Jan Delabie; Richard I Fisher; Joseph M Unger; Michael Leblanc; Louis M Staudt; Elaine S Jaffe; Randy D Gascoyne; Wing C Chan; Dennis D Weisenburger; Timothy Greiner; Rita M Braziel; Thomas P Miller
Journal:  Blood       Date:  2005-10-20       Impact factor: 22.113

Review 3.  The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy.

Authors:  Jessica B Foster; David M Barrett; Katalin Karikó
Journal:  Mol Ther       Date:  2019-02-02       Impact factor: 11.454

4.  Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors.

Authors:  Michal Lotem; Yangbing Zhao; John Riley; Patrick Hwu; Richard A Morgan; Steven A Rosenberg; Maria R Parkhurst
Journal:  J Immunother       Date:  2006 Nov-Dec       Impact factor: 4.456

5.  High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.

Authors:  Yangbing Zhao; Zhili Zheng; Cyrille J Cohen; Luca Gattinoni; Douglas C Palmer; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Journal:  Mol Ther       Date:  2005-09-02       Impact factor: 11.454

6.  Persistent antigenic stimulation alters the transcription program in T cells, resulting in antigen-specific tolerance.

Authors:  Per O Anderson; Barbara A Manzo; Anette Sundstedt; Sophie Minaee; Alistair Symonds; Sabah Khalid; Maria E Rodriguez-Cabezas; Kirsty Nicolson; Suling Li; David C Wraith; Ping Wang
Journal:  Eur J Immunol       Date:  2006-06       Impact factor: 5.532

7.  Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes.

Authors:  Marvin M van Luijn; Martine E D Chamuleau; Maaike E Ressing; Emmanuel J Wiertz; Suzanne Ostrand-Rosenberg; Yuri Souwer; Adri Zevenbergen; Gert J Ossenkoppele; Arjan A van de Loosdrecht; S Marieke van Ham
Journal:  Cancer Immunol Immunother       Date:  2010-09-05       Impact factor: 6.968

8.  Selective modification of antigen-specific T cells by RNA electroporation.

Authors:  Duane A Mitchell; Isaac Karikari; Xiuyu Cui; Weihua Xie; Robert Schmittling; John H Sampson
Journal:  Hum Gene Ther       Date:  2008-05       Impact factor: 5.695

9.  Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation.

Authors:  Xiaojun Liu; Shuguang Jiang; Chongyun Fang; Hua Li; Xuhua Zhang; Fuqin Zhang; Carl H June; Yangbing Zhao
Journal:  Protein Cell       Date:  2017-05-18       Impact factor: 14.870

10.  Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.

Authors:  X Liu; D M Barrett; S Jiang; C Fang; M Kalos; S A Grupp; C H June; Y Zhao
Journal:  Blood Cancer J       Date:  2016-06-03       Impact factor: 11.037

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.